<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39410613</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Anti-SARS-CoV-2 IgM Antibody Levels Measured by an In-House ELISA in a Convalescent Latin Population Persist over Time and Exhibit Neutralizing Capacity to Several Variants of Concern.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics14192209</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The coronavirus, SARS-CoV-2, is the causative agent for COVID-19, first registered in Wuhan, China and responsible for more than 6 million deaths worldwide. Currently, RT-PCR is the gold-standard method for diagnosing COVID-19. However, serological tests are needed for screening acute disease diagnosis and screening large populations during the COVID-19 outbreak.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Herein, we described the development and validation of an in-house enzyme-linked immunosorbent assay (ELISA) for detecting the levels of anti-spike-1-RBD IgM antibody (CovIgM-ELISA) in well-defined serum/plasma panel for screening and identifying subjects infected with SARS-CoV-2 in a Latin population.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In-house CovIgM-ELISA has the format of an indirect ELISA. It was optimized by checkerboard titration using recombinant SARS-CoV-2 spike-S1-RBD protein as an antigen.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that, compared to the RT-PCR as the standard method, the in-house CovIgM-ELISA displayed sensitivities of 96.15% and 93.22% for samples collected up to 30 or 60 days after infection, respectively, as well as 95.59% specificity with 97.3% accuracy. The agreement kappa value (<i>κ</i>) of our CovIgM-ELISA was substantial when compared to RT-PCR (κ = 0.873) and the anti-SARS-CoV-2 IgM ELISA (InBios Int) (κ = 0.684). The IgM levels detected in the population positively correlated with the neutralizing activity against the wild-type, Alpha and Delta variants of concern, but failed to neutralize Omicron.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that our in-house CovIgM-ELISA is a compatible performing assay for the detection of SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Espino</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-8456-2550</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armina-Rodriguez</LastName><ForeName>Albersy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7126-2804</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Health Professions, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocasio-Malavé</LastName><ForeName>Carlimar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0009-7046-1076</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sariol</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-7535-4303</Identifier><AffiliationInfo><Affiliation>Unit of Comparative Medicine, Department of Medicine, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1U01CA260541-01</GrantID><Agency>NCI/NIAID</Agency><Country /></Grant><Grant><GrantID>2020-00272</GrantID><Agency>PRSTRT</Agency><Country /></Grant><Grant><GrantID>2024-000450</GrantID><Agency>DDE-PR</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgM</Keyword><Keyword MajorTopicYN="N">Latin</Keyword><Keyword MajorTopicYN="N">Puerto Rico</Keyword><Keyword MajorTopicYN="N">indirect ELISA</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39410613</ArticleId><ArticleId IdType="pmc">PMC11475847</ArticleId><ArticleId IdType="doi">10.3390/diagnostics14192209</ArticleId><ArticleId IdType="pii">diagnostics14192209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eurosurveilance Editorial Team Note from Editors: World Health Organization declares novel coronavirus (2019-nCoV) sisxth public health emergency of international concern. EuroSurveill. 2020;25:200131e. doi: 10.2807/1560-7917.ES.2020.25.5.200131e.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.5.200131e</ArticleId><ArticleId IdType="pmc">PMC7014669</ArticleId><ArticleId IdType="pubmed">32019636</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . Weekly Epidemiological Update on COVID-19. 66th ed. 2021.  [(accessed on 16 November 2021)].  Available online:  https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-16-november-2021.</Citation></Reference><Reference><Citation>Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Espino A.M., Armina-Rodriguez A., Alvarez L., Ocasio-Malave C., Ramos-Nieves R., Rodriguez Martino E.I., Lopez-Marte P., Torres E.A., Sariol C.A. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024;16:187. doi: 10.3390/v16020187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020187</ArticleId><ArticleId IdType="pmc">PMC10893502</ArticleId><ArticleId IdType="pubmed">38399963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol C.A., Pantoja P., Serrano-Collazo C., Rosa-Arocho T., Armina A., Cruz L., Stone E.T., Arana T., Climent C., Latoni G., et al. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021 doi: 10.3390/v13101972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13101972</ArticleId><ArticleId IdType="pmc">PMC8538099</ArticleId><ArticleId IdType="pubmed">34696403</ArticleId></ArticleIdList></Reference><Reference><Citation>Protocols/CEA . Apprved Guidelines. 2nd ed. Vol. 24 CLSI; Wayne, PA, USA: 2004. Evaluating of precision performance of quantitative measurements methods.</Citation></Reference><Reference><Citation>Taylor S.C., Hurst B., Charlton C.L., Bailey A., Kanji J.N., McCarthy M.K., Morrison T.E., Huey L., Annen K., DomBourian M.G., et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J. Clin. Microbiol. 2021;59:10–1128. doi: 10.1128/JCM.02438-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02438-20</ArticleId><ArticleId IdType="pmc">PMC8092720</ArticleId><ArticleId IdType="pubmed">33500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago G.A., Flores B., Gonzalez G.L., Charriez K.N., Huertas L.C., Volkman H.R., Van Belleghem S.M., Rivera-Amill V., Adams L.E., Marzan M., et al. Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants. Commun. Med. 2022;2:100. doi: 10.1038/s43856-022-00168-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-022-00168-7</ArticleId><ArticleId IdType="pmc">PMC9366129</ArticleId><ArticleId IdType="pubmed">35968047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J. Intern. Med. 2013;4:627–635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3755824</ArticleId><ArticleId IdType="pubmed">24009950</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnet K.B.J. Selection and analytical evaluation of methods-with statistical techniques. In: Burtis C.A., Ashwood E.R., Bruns D.E., editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. Elsevier Saunders; St Louis, MO, USA: 1995.</Citation></Reference><Reference><Citation>Thrusfield M. Veterinary Epidemiology. 2nd ed. Balckewell Science Ltd.; London, UK: 1995.</Citation></Reference><Reference><Citation>Cohen J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 1960;20:37–46. doi: 10.1177/001316446002000104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/001316446002000104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieckowska B.K., Jozwiak P., Moryson W., Stawinska-Witoszynska B. Cohen’s Kappa Coefficient as a Measure toAssess Classification Improvement following the Addition of a New Marker to a Regression Model. Int. J. Environ. Res. Public Health. 2022;19:10213. doi: 10.3390/ijerph191610213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191610213</ArticleId><ArticleId IdType="pmc">PMC9407914</ArticleId><ArticleId IdType="pubmed">36011844</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka S., Higuchi T., Furukawa H., Shimada K., Hashimoto A., Matsui T., Tohma S. False-positive detection of IgM anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with rheumatoid arthritis: Possible effects of IgM or IgG rheumatoid factors on immunochromatographic assay results. SAGE Open Med. 2022;10:20503121221088090. doi: 10.1177/20503121221088090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503121221088090</ArticleId><ArticleId IdType="pmc">PMC8949754</ArticleId><ArticleId IdType="pubmed">35342631</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda E.M., Han X., Park S.H., Suri S., Suryavanshi M. Treatment Patterns Among Patients with Rheumatoid Arthritis in Puerto Rico. Rheumatol. Ther. 2022;9:609–619. doi: 10.1007/s40744-021-00408-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00408-7</ArticleId><ArticleId IdType="pmc">PMC8964873</ArticleId><ArticleId IdType="pubmed">35076904</ArticleId></ArticleIdList></Reference><Reference><Citation>Okba N.M.A., Muller M.A., Li W., Wang C., GeurtsvanKessel C.H., Corman V.M., Lamers M.M., Sikkema R.S., de Bruin E., Chandler F.D., et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg. Infect. Dis. 2020;26:1478–1488. doi: 10.3201/eid2607.200841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.200841</ArticleId><ArticleId IdType="pmc">PMC7323511</ArticleId><ArticleId IdType="pubmed">32267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia W.N., Tan C.W., Foo R., Kang A.E.Z., Peng Y., Sivalingam V., Tiu C., Ong X.M., Zhu F., Young B.E., et al. Serological differentiation between COVID-19 and SARS infections. Emerg. Microbes Infect. 2020;9:1497–1505. doi: 10.1080/22221751.2020.1780951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1780951</ArticleId><ArticleId IdType="pmc">PMC7473126</ArticleId><ArticleId IdType="pubmed">32529906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahallawi W.H. A serological assay to detect human SARS-CoV-2 antibodies. J. Taibah Univ. Med. Sci. 2021;16:57–62. doi: 10.1016/j.jtumed.2020.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtumed.2020.11.011</ArticleId><ArticleId IdType="pmc">PMC7775033</ArticleId><ArticleId IdType="pubmed">33424527</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V., Fabros A., Wang X.Y., Bhandari M., Daghfal D.J., Kulasingam V. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. Clin. Biochem. 2021;90:1–7. doi: 10.1016/j.clinbiochem.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2021.01.003</ArticleId><ArticleId IdType="pmc">PMC7816645</ArticleId><ArticleId IdType="pubmed">33476578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P. Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. J. Virol. Methods. 2020;283:113919. doi: 10.1016/j.jviromet.2020.113919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2020.113919</ArticleId><ArticleId IdType="pmc">PMC7295513</ArticleId><ArticleId IdType="pubmed">32554043</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Tamimi M., Tarifi A.A., Qaqish A., Abbas M.M., Albalawi H., Abu-Raideh J., Salameh M., Khasawneh A.I. Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS ONE. 2023;18:e0281689. doi: 10.1371/journal.pone.0281689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281689</ArticleId><ArticleId IdType="pmc">PMC9928079</ArticleId><ArticleId IdType="pubmed">36787317</ArticleId></ArticleIdList></Reference><Reference><Citation>Amellal H., Assaid N., Charoute H., Akarid K., Maaroufi A., Ezzikouri S., Sarih M. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study. PLoS ONE. 2023;18:e0288557. doi: 10.1371/journal.pone.0288557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0288557</ArticleId><ArticleId IdType="pmc">PMC10337929</ArticleId><ArticleId IdType="pubmed">37437051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaduskar O., Gurav Y.K., Deshpande K., Desphande G.R., Yadav P., Rakhe A., Tilekar B.N., Gomade P., Salunke A., Patil C., et al. Understanding the dynamics of IgM &amp; IgG antibodies in COVID-19-positive patients. Indian. J. Med. Res. 2022;155:565–569. doi: 10.4103/ijmr.IJMR_675_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_675_21</ArticleId><ArticleId IdType="pmc">PMC9807202</ArticleId><ArticleId IdType="pubmed">36124504</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhandynata R.T., Hoffman M.A., Kelner M.J., McLawhon R.W., Reed S.L., Fitzgerald R.L. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. J. Appl. Lab. Med. 2020;5:908–920. doi: 10.1093/jalm/jfaa079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jalm/jfaa079</ArticleId><ArticleId IdType="pmc">PMC7313967</ArticleId><ArticleId IdType="pubmed">32428207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha B., Jadhao S., Hussaini L., Gibson T., Stephens K., Salazar L., Ciric C., Taylor M., Rouphael N., Edupuganti S., et al. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiol. Spectr. 2021;9:e0045821. doi: 10.1128/Spectrum.00458-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00458-21</ArticleId><ArticleId IdType="pmc">PMC8557898</ArticleId><ArticleId IdType="pubmed">34494855</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes-Fernandez B.N., Duconge J., Espino A.M., Ruano G. Personalized health and the coronavirus vaccines-Do individual genetics matter? Bioessays. 2021;43:e2100087. doi: 10.1002/bies.202100087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202100087</ArticleId><ArticleId IdType="pmc">PMC8390434</ArticleId><ArticleId IdType="pubmed">34309055</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A., Crawford K.H.D., Dingens A., Zhu H., Roychoudhury P., Huang M.L., Jerome K.R., Bloom J.D., Greninger A.L. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J. Clin. Microbiol. 2020;58:10–1128. doi: 10.1128/JCM.02107-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02107-20</ArticleId><ArticleId IdType="pmc">PMC7587101</ArticleId><ArticleId IdType="pubmed">32826322</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L., Mascola J.R., Fauci A.S., Collins F.S. A strategic approach to COVID-19 vaccine R&amp;D. Science. 2020;368:948–950. doi: 10.1126/science.abc5312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5312</ArticleId><ArticleId IdType="pubmed">32393526</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M.J., Senefeld J.W., Klassen S.A., Mills J.R., Johnson P.W., Theel E.S., Wiggins C.C., Bruno K.A., Klompas A.M., Lesser E.R., et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv. 2020 doi: 10.1101/2020.08.12.20169359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.12.20169359</ArticleId><ArticleId IdType="pmc">PMC7430623</ArticleId><ArticleId IdType="pubmed">32817978</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.D., Wang K., Roltgen K., Nielsen S.C.A., Roach J.C., Naccache S.N., Yang F., Wirz O.F., Yost K.E., Lee J.Y., et al. Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report. Vaccines. 2022;11:5. doi: 10.3390/vaccines11010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010005</ArticleId><ArticleId IdType="pmc">PMC9861578</ArticleId><ArticleId IdType="pubmed">36679852</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingler J., Weiss S., Itri V., Liu X., Oguntuyo K.Y., Stevens C., Ikegame S., Hung C.T., Enyindah-Asonye G., Amanat F., et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv. 2020 doi: 10.1101/2020.08.18.20177303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.18.20177303</ArticleId><ArticleId IdType="pmc">PMC7654883</ArticleId><ArticleId IdType="pubmed">33173891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Bhattacharya M., Sharma A.R., Mallik B. Omicron (B.1.1.529)—A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int. J. Biol. Macromol. 2022;219:980–997. doi: 10.1016/j.ijbiomac.2022.07.254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.07.254</ArticleId><ArticleId IdType="pmc">PMC9359758</ArticleId><ArticleId IdType="pubmed">35952818</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Daly M.M. Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies. Diagnostics. 2024;14:519. doi: 10.3390/diagnostics14050519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics14050519</ArticleId><ArticleId IdType="pmc">PMC10931201</ArticleId><ArticleId IdType="pubmed">38472991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>